Literature DB >> 12869035

Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia.

D Sansonno1, G Lauletta, L Nisi, P Gatti, F Pesola, N Pansini, F Dammacco.   

Abstract

Hepatitis C virus (HCV) infection has been detected in a large proportion of patients with mixed cryoglobulinaemia (MC). Circulating 'free' non-enveloped HCV core protein has been demonstrated in HCV-infected patients, and this suggests its possible involvement in the formation of cryoprecipitable immune complexes (ICs). Thirty-two anti-HCV, HCV RNA-positive patients with type II MC were evaluated. Non-enveloped HCV core protein, HCV RNA sequences, total IgM, rheumatoid factor (RF) activity, IgG and IgG subclasses, C3 and C4 fractions, C1q protein and C1q binding activity were assessed in both cryoprecipitates and supernatants. Non-enveloped HCV core protein was demonstrated in 30 of 32 (93.7%) type II MC patients. After separation of cold-precipitable material, the protein was removed completely from supernatant in 12 patients (40%), whereas it was enriched in the cryoprecipitates of the remaining 18. In addition, HCV RNA and IgM molecules with RF activity were concentrated selectively in the cryoprecipitates. Differential precipitation was found for both total IgG and IgG subclasses, as they were less represented in the cryoglobulins and no selective enrichment was noted. Immunological characterization of HCV core protein-containing cryoprecipitating ICs after chromatographic fractionation showed that the IgM monoclonal component had RF activity, whereas anti-HCV core reactivity was confined to the IgG fraction. C1q enrichment in addition to high avidity of ICs for C1q binding in the cryoprecipitates suggest that complement activation may occur through the C1q protein pathway. The present data demonstrate that non-enveloped HCV core protein is a constitutive component of cryoprecipitable ICs in type II MC patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869035      PMCID: PMC1808767          DOI: 10.1046/j.1365-2249.2003.02204.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor.

Authors:  B L Lim; K B Reid; B Ghebrehiwet; E I Peerschke; L A Leigh; K T Preissner
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

Review 2.  The molecular virology of hepatitis C.

Authors:  M E Major; S M Feinstone
Journal:  Hepatology       Date:  1997-06       Impact factor: 17.425

3.  Peripheral deletion of rheumatoid factor B cells after abortive activation by IgG.

Authors:  H Tighe; K Warnatz; D Brinson; M Corr; W O Weigle; S M Baird; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 4.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

5.  Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients.

Authors:  F Komatsu; K Takasaki
Journal:  Liver       Date:  1999-10

6.  Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  D Sansonno; L Gesualdo; C Manno; F P Schena; F Dammacco
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

7.  Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates.

Authors:  A Sabile; G Perlemuter; F Bono; K Kohara; F Demaugre; M Kohara; Y Matsuura; T Miyamura; C Bréchot; G Barba
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

Review 8.  Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes.

Authors:  J McLauchlan
Journal:  J Viral Hepat       Date:  2000-01       Impact factor: 3.728

Review 9.  Human complement regulators: a major target for pathogenic microorganisms.

Authors:  G Lindahl; U Sjöbring; E Johnsson
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

10.  Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia.

Authors:  T Tanaka; J Y Lau; M Mizokami; E Orito; E Tanaka; K Kiyosawa; K Yasui; Y Ohta; A Hasegawa; S Tanaka
Journal:  J Hepatol       Date:  1995-12       Impact factor: 25.083

View more
  32 in total

Review 1.  Cryoglobulins in chronic hepatitis C virus infection.

Authors:  M Trendelenburg; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

2.  Anti-C1q antibodies in hepatitis C virus infection.

Authors:  D Saadoun; S Sadallah; M Trendelenburg; N Limal; D Sene; J C Piette; J A Schifferli; P Cacoub
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 3.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

4.  Persistence of Circulating Hepatitis C Virus Antigens-Specific Immune Complexes in Patients with Resolved HCV Infection.

Authors:  Ke-Qin Hu; Wei Cui
Journal:  Dig Dis Sci       Date:  2018-03-08       Impact factor: 3.199

5.  Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection.

Authors:  D Sansonno; G Lauletta; M Montrone; G Grandaliano; F P Schena; F Dammacco
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

6.  Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Authors:  E Riva; F Maggi; F Abbruzzese; F Bellomi; G Giannelli; A Picardi; C Scagnolari; A Folgori; E Spada; E Piccolella; F Dianzani; G Antonelli
Journal:  Med Microbiol Immunol       Date:  2008-08-12       Impact factor: 3.402

Review 7.  Hepatitis C virus and neurological damage.

Authors:  Shilu Mathew; Muhammed Faheem; Sara M Ibrahim; Waqas Iqbal; Bisma Rauff; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-28

Review 8.  Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis.

Authors:  Aman Sharma; Kusum Sharma
Journal:  J Clin Exp Hepatol       Date:  2013-07-08

9.  Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy.

Authors:  Paolo Conca; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

10.  Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage.

Authors:  Domenico Sansonno; Felicia Anna Tucci; Berhane Ghebrehiwet; Gianfranco Lauletta; Ellinor I B Peerschke; Vincenza Conteduca; Sabino Russi; Pietro Gatti; Loredana Sansonno; Franco Dammacco
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.